scientific article published on 28 September 2014

AttributesValues
rdf:type
description
  • wetenschappelijk artikel (nl)
  • наукова стаття, опублікована в жовтні 2014 (uk)
  • article scientifique publié en 2014 (fr)
  • scientific article published on 28 September 2014 (en)
  • artículu científicu espublizáu en setiembre de 2014 (ast)
  • im September 2014 veröffentlicher wissenschaftlicher Artikel (de)
publication date
publication date
cites work
cites work
author name string
author name string
  • Christoph Zielinski
  • Gunter von Minckwitz
  • Gilles Romieu
  • Norbert Marschner
  • Corinne Veyret
  • Eduard Vrdoljak
  • Ulrich Freudensprung
  • Stefanie Srock
  • Cristian Villanueva
  • Sabine de Ducla
  • István Lang
rdfs:label
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (en)
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (nl)
skos:prefLabel
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (en)
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (nl)
name
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (en)
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (nl)
author
author
title
title
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial (en)
page(s)
page(s)
  • 1269-1278
instance of
instance of
main subject
main subject
PubMed ID
PubMed ID
PubMed ID
  • 25273342
Faceted Search & Find service v1.16.117 as of May 05 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software